Characteristics of patients with PCNSL treated with chemotherapy alone or with immunochemotherapy
| . | All patients (N = 4691) . | Chemotherapy (N = 1544) . | Immunochemotherapy (N = 3147) . | P . | ||
|---|---|---|---|---|---|---|
| Age, median (interquartile range) | 66 (57-73) | 66 | (56-73) | 66 | (57-73) | .57 |
| Sex, N (%, row)∗ | ||||||
| Male | 2400 | 833 | (34.7) | 1567 | (65.3) | .008 |
| Female | 2291 | 711 | (31.0) | 1580 | (69.0) | |
| Race/ethnicity, N (%, row) | ||||||
| WNH | 3680 | 1146 | (31.1) | 2534 | (68.9) | <.001 |
| Hispanic (any race) | 411 | 170 | (41.4) | 241 | (58.6) | |
| Black | 259 | 107 | (41.3) | 152 | (58.7) | |
| Asian or other | 297 | 98 | (33.0) | 199 | (67.0) | |
| Unrecorded | 44 | 23 | (52.3) | 21 | (47.7) | |
| HIV status, N (%, row) | ||||||
| Negative | 4534 | 1462 | (32.2) | 3072 | (67.8) | < .001 |
| Positive | 157 | 82 | (52.2) | 75 | (47.8) | |
| Charlson-Deyo Score, N (%, row) | ||||||
| 0 | 3017 | 1003 | (33.2) | 2014 | (66.8) | .17 |
| 1 | 924 | 302 | (32.7) | 622 | (67.3) | |
| 2 | 403 | 115 | (28.5) | 288 | (71.5) | |
| ≥3 | 347 | 124 | (35.7) | 223 | (64.3) | |
| Primary site of PCNSL, N (%, row) | ||||||
| Brain | 3929 | 1327 | (33.8) | 2602 | (66.2) | .04 |
| Spinal cord | 107 | 35 | (32.7) | 72 | (67.3) | |
| Eye | 14 | 3 | (21.4) | 11 | (78.6) | |
| Meninges | 16 | 3 | (18.8) | 13 | (81.3) | |
| Other/unspecified | 625 | 176 | (28.2) | 449 | (71.8) | |
| Prior malignancy, N (%, row) | ||||||
| PCNSL as first cancer | 3953 | 1323 | (33.5) | 2630 | (66.5) | .066 |
| Prior malignancy | 738 | 221 | (29.9) | 517 | (70.1) | |
| Chemotherapy, N (%, row) | ||||||
| Single agent | 1715 | 618 | (36.0) | 1097 | (64.0) | <.001 |
| Multiple agents | 2911 | 891 | (30.6) | 2020 | (69.4) | |
| Unspecified | 65 | 35 | (53.8) | 30 | (46.2) | |
| Insurance, N (%, row) | ||||||
| Private insurance | 3662 | 1172 | (32.0) | 2490 | (68.0) | .008 |
| Medicaid | 408 | 161 | (39.5) | 247 | (60.5) | |
| Medicare | 347 | 129 | (37.2) | 218 | (62.8) | |
| Other government | 84 | 20 | (23.8) | 64 | (76.2) | |
| Not insured | 120 | 41 | (34.2) | 79 | (65.8) | |
| Insurance status unknown | 70 | 21 | (30.0) | 49 | (70.0) | |
| Hospital type, N (%, row)† | ||||||
| Community | 1922 | 726 | (37.8) | 1196 | (62.2) | < .001 |
| Academic | 2769 | 818 | (29.5) | 1951 | (70.5) | |
| PCNSL cases/y, N (%, row) | ||||||
| 0-5 | 3100 | 1164 | (37.5) | 1936 | (62.5) | <.001 |
| >5 | 1591 | 380 | (23.9) | 1211 | (76.1) | |
| . | All patients (N = 4691) . | Chemotherapy (N = 1544) . | Immunochemotherapy (N = 3147) . | P . | ||
|---|---|---|---|---|---|---|
| Age, median (interquartile range) | 66 (57-73) | 66 | (56-73) | 66 | (57-73) | .57 |
| Sex, N (%, row)∗ | ||||||
| Male | 2400 | 833 | (34.7) | 1567 | (65.3) | .008 |
| Female | 2291 | 711 | (31.0) | 1580 | (69.0) | |
| Race/ethnicity, N (%, row) | ||||||
| WNH | 3680 | 1146 | (31.1) | 2534 | (68.9) | <.001 |
| Hispanic (any race) | 411 | 170 | (41.4) | 241 | (58.6) | |
| Black | 259 | 107 | (41.3) | 152 | (58.7) | |
| Asian or other | 297 | 98 | (33.0) | 199 | (67.0) | |
| Unrecorded | 44 | 23 | (52.3) | 21 | (47.7) | |
| HIV status, N (%, row) | ||||||
| Negative | 4534 | 1462 | (32.2) | 3072 | (67.8) | < .001 |
| Positive | 157 | 82 | (52.2) | 75 | (47.8) | |
| Charlson-Deyo Score, N (%, row) | ||||||
| 0 | 3017 | 1003 | (33.2) | 2014 | (66.8) | .17 |
| 1 | 924 | 302 | (32.7) | 622 | (67.3) | |
| 2 | 403 | 115 | (28.5) | 288 | (71.5) | |
| ≥3 | 347 | 124 | (35.7) | 223 | (64.3) | |
| Primary site of PCNSL, N (%, row) | ||||||
| Brain | 3929 | 1327 | (33.8) | 2602 | (66.2) | .04 |
| Spinal cord | 107 | 35 | (32.7) | 72 | (67.3) | |
| Eye | 14 | 3 | (21.4) | 11 | (78.6) | |
| Meninges | 16 | 3 | (18.8) | 13 | (81.3) | |
| Other/unspecified | 625 | 176 | (28.2) | 449 | (71.8) | |
| Prior malignancy, N (%, row) | ||||||
| PCNSL as first cancer | 3953 | 1323 | (33.5) | 2630 | (66.5) | .066 |
| Prior malignancy | 738 | 221 | (29.9) | 517 | (70.1) | |
| Chemotherapy, N (%, row) | ||||||
| Single agent | 1715 | 618 | (36.0) | 1097 | (64.0) | <.001 |
| Multiple agents | 2911 | 891 | (30.6) | 2020 | (69.4) | |
| Unspecified | 65 | 35 | (53.8) | 30 | (46.2) | |
| Insurance, N (%, row) | ||||||
| Private insurance | 3662 | 1172 | (32.0) | 2490 | (68.0) | .008 |
| Medicaid | 408 | 161 | (39.5) | 247 | (60.5) | |
| Medicare | 347 | 129 | (37.2) | 218 | (62.8) | |
| Other government | 84 | 20 | (23.8) | 64 | (76.2) | |
| Not insured | 120 | 41 | (34.2) | 79 | (65.8) | |
| Insurance status unknown | 70 | 21 | (30.0) | 49 | (70.0) | |
| Hospital type, N (%, row)† | ||||||
| Community | 1922 | 726 | (37.8) | 1196 | (62.2) | < .001 |
| Academic | 2769 | 818 | (29.5) | 1951 | (70.5) | |
| PCNSL cases/y, N (%, row) | ||||||
| 0-5 | 3100 | 1164 | (37.5) | 1936 | (62.5) | <.001 |
| >5 | 1591 | 380 | (23.9) | 1211 | (76.1) | |
All percentages are by row to illustrate proportions of patients receiving chemotherapy or immunochemotherapy within each subgroup.
Community designation includes the NCDB categories of community and comprehensive community centers; Academic designation includes the NCDB categories of academic/Research and integrated network centers.